ADAPTVAC
Updated 420 days ago
Ole Maaløes Vej 3, 2200 København N Denmark
AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines, owned by the inventors of the novel proprietary and ground-breaking capsid Virus-Like Particle (cVLP) platform technology spun out from the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders.
Registration numbers: 38732730 (W)